Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | FABP2 | P12104 | 1/20 | 0.37 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2088760 | 1.00 | MEN1 (0.41) | MEN1KMT2ALMNASMN1; SMN2GAA | |
| SCHEMBL2334833 | 0.77 | EPHX2 (0.43) | MEN1KMT2AALDH1A1PTGS1PTGS2 | |
| SCHEMBL27010080 | 0.77 | TAAR1 (0.41) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL29643341 | 0.76 | SIGMAR1 (0.50) | AKR1C3AKR1C2 | |
| SCHEMBL7366363 | 0.76 | SIGMAR1 (0.50) | AKR1C3AKR1C2 | |
| SCHEMBL29643326 | 0.76 | SIGMAR1 (0.50) | AKR1C3AKR1C2 | |
| SCHEMBL173510 | 0.76 | SIGMAR1 (0.50) | AKR1C3AKR1C2 | |
| SCHEMBL173511 | 0.76 | SIGMAR1 (0.50) | AKR1C3AKR1C2 | |
| SCHEMBL12550511 | 0.75 | DDB1 (0.48) | MEN1KMT2ASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL755703 | 0.75 | ALDH1A1 (0.43) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250288650-A1 | Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-09-18 | — | — | US | disclosed |
| EP-4611792-A1 | THERAPEUTIC REGIMENS AND METHODS FOR TREATMENT OF CARDIOVASCULAR RISK FACTORS USING A GLP-1R AND GCGR AGONIST | Spitfire Pharma LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250262280-A1 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | SPITFIRE PHARMA LLC (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4587045-A2 | THERAPEUTIC REGIMENS AND METHODS FOR REDUCING BODY WEIGHT IN A SUBJECT WITH FATTY LIVER DISEASE USING A GLP-1R AND GCGR AGONIST | Spitfire Pharma LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250134963-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | SPITFIRE PHARMA LLC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12171806-B2 | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists | SPITFIRE PHARMA LLC (MD) | 2024-12-24 | — | — | US | disclosed |
| US-20240277815-A1 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240269238-A1 | Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2024098071-A1 | THERAPEUTIC REGIMENS AND METHODS FOR TREATMENT OF CARDIOVASCULAR RISK FACTORS USING A GLP-1R AND GCGR AGONIST | SPITFIRE PHARMA LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240148879-A1 | GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-05-09 | — | — | US | disclosed |
| WO-2024059753-A2 | THERAPEUTIC REGIMENS AND METHODS FOR REDUCING BODY WEIGHT IN A SUBJECT WITH FATTY LIVER DISEASE USING A GLP-1R AND GCGR AGONIST | SPITFIRE PHARMA LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-117202924-A | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balance agonists | 斯皮特弗尔制药有限责任公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4255564-A1 | THERAPEUTIC REGIMENS AND METHODS FOR LOWERING BLOOD GLUCOSE AND OR BODY WEIGHT USING GLP-1R AND GCGR BALANCED AGONISTS | Spitfire Pharma LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230104501-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | SPITFIRE PHARMA LLC (US) | 2023-04-06 | — | — | US | disclosed |
| US-11541028-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | ALTIMMUNE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-4106796-A1 | GLP-1R AND GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | Spitfire Pharma LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| CN-115427065-A | GLP-1R and GCGR agonists, formulations, and methods of use | 斯皮特弗尔制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2022178366-A1 | GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | SPITFIRE PHARMA LLC (US) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022125598-A1 | THERAPEUTIC REGIMENS AND METHODS FOR LOWERING BLOOD GLUCOSE AND OR BODY WEIGHT USING GLP-1R AND GCGR BALANCED AGONISTS | SPITFIRE PHARMA LLC (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288650-A1 | Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | MEN1 1359/4885KMT2A 576/4885LMNA 2962/4885 |
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | MEN1 1818/4885KMT2A 704/4885LMNA 2458/4885 |
| US-12171806-B2 | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists | GLP1R, GCGR, GIPR | MEN1 1493/4885KMT2A 870/4885LMNA 3781/4885 |
| US-20250134963-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | GLP1R, GCGR, GIPR | MEN1 1493/4885KMT2A 870/4885LMNA 3781/4885 |
| US-20240148879-A1 | GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | GIPR, GLP1R, GCGR | MEN1 501/4885KMT2A 2276/4885LMNA 3569/4885 |
| US-20240269238-A1 | Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | MEN1 1261/4885KMT2A 739/4885LMNA 2785/4885 |
| US-20250262280-A1 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | GLP1R, GCGR, GPR119 | MEN1 2065/4885KMT2A 2583/4885LMNA 3600/4885 |
| US-11541028-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | GLP1R, IAPP, GPR119 | MEN1 1281/4885KMT2A 4387/4885LMNA 1854/4885 |
| US-20240277815-A1 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | MEN1 1818/4885KMT2A 704/4885LMNA 2458/4885 |
| US-20230104501-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | GLP1R, GCGR, GIPR | MEN1 1493/4885KMT2A 870/4885LMNA 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.